Alexander brings over 30 years of CEO and Board member experience across the biotech industry, growing and advancing biopharmaceutical companies with a focus on rare and orphan diseases.

Alexander began his career at McKinsey & Co. in 1989 after which he joined Genzyme Europe in 1994. At Genzyme, he held several executive roles, including leading a global joint venture with Pharming NV to develop and commercialize the enzyme human alpha-glucosidase as a treatment for Pompe’s disease. Thereafter he led a number of public and private biotech companies across Europe, including two towards successful investor exits. He currently serves on the boards of several biotech companies in the USA, the United Kingdom and continental Europe. Alexander holds an MS in Pharmacy and Pharmacology from the University of Amsterdam and an MBA from Stanford University.

Ben brings over 25 years of industry experience across all stages of drug development, including rare disease indications like Niemann-Pick Disease. He served as CEO of Vtesse and oversaw the completion of the pivotal study as well as the subsequent acquisition by Sucampo Pharmaceuticals in 2017.

Before this, Ben was COO at Omthera where he played a crucial role in the development and approval of the company’s candidate for hypertriglyceridemia, Omthera’s IPO and eventual acquisition by AstraZeneca.  Earlier in his career, Ben held executive positions in development, quality and operations at MedImmune, Xoma Corporation and Centocor BV. He also currently serves as chairman of the board at Mosanna Therapeutics.

Edward is Founder and Managing Partner at BioGeneration Ventures (BGV) and combines over 20 years of experience in venture capital, pharma licensing, drug development and translational research.

He was founding investor and board member of Acerta Pharma (acquired by Astra Zeneca for $7B) and currently serves on the boards of several BGV portfolio companies.

Michael is an experienced life science entrepreneur and General Partner at BioMedPartners. Michael serves on the board of directors of various portfolio companies.

In addition, he coaches start-ups in Switzerland for Innosuisse, the governmental commission of technology and innovation. Before joining BioMedPartners, Michael was founder and CSO of GlycoVaxyn (acquired by GSK) and chairman of Inositec (acquired by Vifor).

Nick serves on the board of Scenic as an Observer, representing investor Oxford Science Enterprises, where he is a Partner. He brings experience from a career spent in investing and corporate finance.

Nick  joined Oxford Sciences Enterprises from Valiance, a MedTech-focused venture capital firm. He was previously an investor at large cap buyout private equity firm Nordic Capital. Prior to that he began his career as an investment banker at Bank of America Merrill Lynch.

25 years of experience in biotech, including 14 years in investment banking. Oscar joined Scenic in July 2020 as CEO and Board Director.

He is involved as NED with a number of other biotech companies across Europe and co-owner of Kaapse Brouwers in Rotterdam.

Co-founder of Scenic Biotech, Haplogen, and Haplogen Genomics.

Former member of the Ludwig Institute for Cancer Research in Oxford, principle investigator at CeMM, Vienna, and postdoc at the Broad Institute, Cambridge, MA.

Stephan is founding partner of the Nordic Life Science Venture fund, Eir Ventures. Prior to launching Eir Ventures, Stephan was part of setting up Novo Seeds, the early stage company creation and investment arm of Novo Holdings.

During his 12 years at Novo Seeds, he led creation and funding of more than 25 companies in Europe, with a particular focus on Scandinavia. Stephan has extensive operational experience from management and research scientist roles in European and US Biotech and holds a PhD in Protein Chemistry and immunology from UCSF.​

Stéphane Verdood has an MBA and a Master’s degree in commercial engineering from the Catholic University of Leuven. Stéphane is a recognized venture capitalist. 

He started his career with Arthur Andersen as information technology auditor. After having led the mergers and acquisitions division of Arthur Andersen in Belgium from 1989 to 1995, he founded and led Arthur Andersen’s business consulting division in Belgium and Luxembourg. He served on the European Board of Partners of Arthur Andersen. Since October 2000, before he joined Vesalius Biocapital, Stéphane has been active as a venture coach for early-stage companies. He was a founder and managing partner at Value4Growth, a specialized Life Science consulting firm supporting start-up companies in all aspects of company formation, product strategy and fund raising.Stéphane is a founding partner of Vesalius Biocapital Funds specialized in venture capital for European biotechnology companies. Since 2007 Vesalius has invested in more than 20 biotech companies. During his career he has worked in the US, Switzerland, France, the Netherlands, the UK and Portugal. Fund raising to set up Fund I in 2007 and Fund II in 2011.

Thijs is a Partner at Inkef and has been with the firm since 2016. He combines his medical background with strategy consulting experience, focusing on healthcare and technology investments.

Prior to Inkef, Thijs was a strategy consultant at the Boston Consulting Group and helped establish the Amsterdam Health and Technology Institute in 2014. He is a medical doctor who graduated from Leiden University and has co-authored several scientific papers in diabetes.

Thijs currently serves on the boards of TargED BioPharmaceuticals, iOnctura, ViCentra, Castor, and Scenic Biotech, with previous board positions at Aidence (acquired by RadNet) and Calypso Biotech (acquired by Novartis).

Alexandra is President & CEO of Sensorium Therapeutics. Prior to that, she fulfilled multiple leadership roles including, Founding COO at Editas Medicine, VP at Millenium Pharmaceuticals, SVP at Cerulean Pharma, and most recently President & CEO of Cedilla Therapeutics.She also serves on the board of RegenxBio.

Chas is Pro-Vice Chancellor for Innovation and Professor of Translational Medicine at the University of Oxford.

He is Director of the Centre for Medicines Discovery in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology. Chas is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and pharma drug discovery programmes.

Dr. Abu-Remaileh is an Assistant Professor of Chemical Engineering and Genetics and Institute Scholar of ChEM-H at Stanford University.

The Abu-Remaileh lab is interested in identifying novel pathways that enable cellular and organismal adaptation to metabolic stress and changes in environmental conditions. They also study how these pathways go awry in human diseases such as cancer, neurodegeneration and metabolic syndrome, in order to engineer new therapeutic modalities. To address these questions, the lab uses multidisciplinary approaches, including metabolomics, proteomics and functional genomics, to study the biochemical functions of the lysosome in vitro and in vivo. His lab has made several fundamental discoveries in the fields of lysosome biology and neurodegenerative diseases and developed major tools that are currently used widely to probe subcellular metabolism.

Dr. Abu-Remaileh has received several major awards for his work including Innovators under 35 from MIT technology Review and the New Innovator award from NIH, R.R. Bensley Award in Cell Biology and was named a Pew-Stewart Scholar.

Olivier is a senior leader in pharma strategic development for early- and late-phase products, bringing years of scientific, clinical and regulatory hand-on experience, and business insights, in rare genetic metabolic disorders and orphan drugs.

He has a strong industry track record, most recently as co-founder and former CEO of Azafaros focused on small molecules for lysosomal storage disorders, and before that as Senior Director Rare Disease (Idorsia), Global Life Cycle Leader (Actelion), Scientific Expert & Program leader (Hoffmann-La Roche). He is also a Venture Partner at BiomedVC.

Dr. Kiener is an industry veteran with extensive experience in drug development across the entire value chain of biopharmaceutical research and development and has led or contributed to the development and regulatory approval of multiple drugs. Peter was the former CSO at Sucampo, until the company’s acquisition by Mallinckrodt in February 2018. Peter held several executive leadership roles including as the Executive Vice President and Global Head of Biologics Research and Development at MedImmune LLC, which became the global biologics arm of AstraZeneca.

Dr. Kiener earned a bachelor’s degree in chemistry from the University of Lancaster, UK and a doctorate of philosophy in biochemistry from the University of Oxford. He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications.

Co-founder of Scenic Biotech, Haplogen, and Haplogen Genomics.Former member of the Ludwig Institute for Cancer Research in Oxford, principle investigator at CeMM, Vienna, and postdoc at the Broad Institute, Cambridge, MA. Sebastian is also a Scenic Board Observer.

20+ year career in award-winning Genomics research. Scientific Director and Group Leader at The Netherlands Cancer Institute and former Fellow at the Whitehead Institute for Biomedical Research in Cambridge USA.

Co-founder of Haplogen, Haplogen Genomics and Scenic Biotech.